Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. - Wikidata - awgldk - TriplyDB

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

http://www.wikidata.org/entity/Q35753251

about

Trial Watch Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Targeting gastrointestinal stromal tumors: the role of regorafenib Targeting the indoleamine 2,3-dioxygenase pathway in cancer Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Universes collide: combining immunotherapy with targeted therapy for cancer The GIST of targeted therapy for malignant melanoma Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer Trial watch: IDO inhibitors in cancer therapy Innate and adaptive immune cells in the tumor microenvironment Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity Non-Darwinian dynamics in therapy-induced cancer drug resistance.Current Immunotherapies for Sarcoma: Clinical Trials and Rationale Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Dasatinib promotes Th1-type responses in granzyme B expressing T-cells Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).Updates on the management of gastrointestinal stromal tumors.IDO is a nodal pathogenic driver of lung cancer and metastasis development.Indoleamine 2,3 dioxygenase and metabolic control of immune responses.Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future.Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Big opportunities for small molecules in immuno-oncology.IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape Gene therapy for cancer: present status and future perspective

P2860

Q24618653-3313282C-3F3E-4CDA-A55E-AE3379E779C6 Q26738359-059C75C2-8005-4FFF-B0B1-775A99DDBD09 Q26747162-BBAE0437-7D59-429F-BEA3-E0A1698D34C3 Q26775471-8786FBE5-D013-4755-9E17-9C41632FA713 Q26783748-3E8BB2A4-0456-4C02-9B7A-DFA664348923 Q26796309-14411C89-ACCB-4DEB-9C6C-6DF9AD163F5F Q26825316-3CA7A71D-3300-4F68-9CF0-84CC23AD5580 Q26827092-4ED97450-8748-4331-9E96-9C323A1B95CB Q26861293-F13945DB-84C4-43B3-A02D-D812B682E5E7 Q27006866-64275AEB-1160-4C87-9AFF-893DB9BD66FF Q27008342-FBC5F18E-8863-436D-8BEB-0C1A4821BDD2 Q27025344-5D538F08-FB0B-4641-A14D-302DC72B3D62 Q27320733-58468B2A-AABD-4B2D-BD04-1332B76E6F47 Q27324745-EA7F686D-8684-4D74-B376-F8773CCB96C2 Q28067036-6D439DAA-FA9C-4B35-B68E-DC4C6E476FDD Q28820954-B0338A03-640D-4FD4-B3A1-A138C00D2716 Q30491702-770DFE7A-389C-4180-B0BC-D22C1B66BCA2 Q33404602-3EC267DF-C429-429E-83A3-F243D6AA169D Q33560776-C7849FF5-34E2-4166-B51B-13F9054032BF Q33572246-95FCC614-3811-45EA-94A7-908B7153CC1B Q33572971-B85E470C-F282-443C-9068-672C2A36E8A0 Q33593877-5F60648D-D067-45F1-B3F8-78CAAB88A9E5 Q33807742-081422D8-729D-45A8-9CC3-B9A23E11EA3C Q33859814-2B74B9B3-005A-424C-AD53-FEBC1C6E7F10 Q33894390-0C421EFC-FFF7-4B46-8D83-8AFEC876841A Q33899522-4DC93812-0BA9-4B13-948C-A890DD9F65D7 Q33930605-5E51407D-8CD3-48D6-B580-ABB54B485058 Q34028872-C3A4A5D0-F87A-40DE-BAD4-50589232E216 Q34256921-FBCDDCDB-1B8F-42C9-ACBF-72EC74F25558 Q34289698-11150D35-CE4D-4BFB-B2D7-E9B8020F34AE Q34308495-F934A78E-47B5-4DA4-AFDF-B11708BEFBDB Q34312571-28F4F9C5-42BB-4238-82D3-148EA1C33E8C Q34414152-B2FBD54E-F6C2-491A-9944-825DAEC8EAB1 Q34464096-5EF17799-AD23-4204-B5A5-63D48720CC8C Q34487689-23FDA034-2EF3-4659-8531-CAA0F55F6A9B Q34512092-EA5A209B-A3B1-44CD-A048-095BCA808EE0 Q34913785-08C53F73-4CE0-45B6-A49F-E6FC15CD3AC3 Q35184110-C2915E5E-2B0B-4D75-B6B8-299690054A7C Q35300077-EBA8E292-EB09-438B-AE92-C9DEB71CE860 Q35673900-C886F50A-573C-4670-8F0B-1B638368F302

P2860

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

http://www.wikidata.org/entity/Q35753251

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@ast

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@en

type

label

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@ast

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@en

prefLabel

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@ast

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@en

P1433

Q35753251-5FCB0E58-A896-4A0B-AB46-F6162BB2FB11

P1476

Q35753251-C196F02A-87DD-496F-B586-60EC77F28F9E

P2093

Q35753251-0FB66444-971C-4ABD-8193-FFA043D2DE52

Q35753251-10F90C7F-996C-433D-9FD6-ADED49616844

Q35753251-11837C67-B6C2-4669-88C4-AAC8885CDF7A

Q35753251-1FDAEE65-9850-4592-A294-8A57E048A432

Q35753251-4931DC58-B1D8-469E-9A45-CB4D4EA8A869

Q35753251-55553D4A-9FC3-406D-859B-7887775A4FF1

Q35753251-55A4D2D6-C62F-4DC4-91C2-ED5F71ACA27F

Q35753251-8022CFD7-75ED-4F04-96CA-9F3C41CD205B

Q35753251-8749884E-DF97-48AC-B06F-778DD7ADFE5D

Q35753251-AE6A9306-0B30-47FF-80D7-A403BBFA74E8

P2860

Q35753251-060DEB79-3954-46FA-BB33-22A6993D0E51

Q35753251-088FA4AC-B5CC-47F5-9F90-8DB03B629AF6

Q35753251-0960940A-489E-4076-BC6B-7A2888606488

Q35753251-0B2DB574-E191-4635-9886-D52F1168BB1B

Q35753251-1630D295-E0A0-4F93-A5AD-1F1091653124

Q35753251-180832E2-6886-4EFE-9322-23A6D8E9F671

Q35753251-1CC56D7D-68F8-4284-B075-07E805E4B5F3

Q35753251-1CCF59C3-4511-4540-B6B0-65C0D4535275

Q35753251-27BE7FCF-FF49-4ADC-AD38-E0D82089471B

Q35753251-2DA2FBD7-3F7C-4E60-BF4C-4D4871356613

P2888

Q35753251-033C255F-BB42-40C9-9D69-943FC40E35E7

P304

Q35753251-7A4263CD-5334-4FD5-B89B-0FBA22055CDE

P31

Q35753251-E17E0517-D7B4-4000-8F5B-D96B405797B9

P356

Q35753251-9D39CF06-FE54-439F-B601-882992D114E5

P407

Q35753251-21332BBC-B50B-4464-BF65-05C48937BCEA

P433

Q35753251-101A7B31-A94B-40B0-A84B-155DD6EF8944

P478

Q35753251-C07130B2-8290-400F-8F02-CB8779EAE281

P50

Q35753251-1EE3C883-CFCF-42CC-BC02-5FC9AC189C29

Q35753251-7B71B88E-2767-445D-A426-A2F6909E53EC

P577

Q35753251-4A94AD6D-F6AF-4837-BC18-22B024FA58C1

P5875

Q35753251-3A1B0246-8F6E-44B7-8AE5-09C6D8E6C761

P698

Q35753251-2338BBA8-81CA-4C4B-921F-624C98A29555

P932

Q35753251-303F8074-C97A-4D69-A937-813E2E3D41A3

P356

P1433

Nature Medicine

P1476

Imatinib potentiates antitumor ...... through the inhibition of Ido.

@en

P2093

Charlotte Ariyan

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Eric C Sorenson

http://www.w3.org/2001/XMLSchema#string

Ferdinand Rossi

http://www.w3.org/2001/XMLSchema#string

Hebroon Obaid

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Lee M Ocuin

http://www.w3.org/2001/XMLSchema#string

Michael J Cavnar

http://www.w3.org/2001/XMLSchema#string

Peter Besmer

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Mad2 overexpression promotes aneuploidy and tumorigenesis in mice

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

IDO expression by dendritic cells: tolerance and tryptophan catabolism

P2888

P304

1094-1100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2438

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

James P. Allison

P577

2011-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51602013

http://www.w3.org/2001/XMLSchema#string

P698

21873989

http://www.w3.org/2001/XMLSchema#string

P932

3278279

http://www.w3.org/2001/XMLSchema#string